|
Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. |
|
Rambach G, Oberhauser H, Speth C, Lass-Flörl C.
Med Mycol. 2011 Nov;49(8):856-63.
|
|
|
|
| |
Clinical performance of (1,3)-{beta}-d-glucan assay in early diagnosis of nosocomial Candida blood stream infections. |
|
Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, Mularoni A, Bassetti M, Viscoli C.
Clin Vaccine Immunol. 2011 Oct 12.
|
|
|
|
| |
Diagnostic performance of 1,3-β-D-Glucan in neonatal and pediatric patients with candidemia. |
|
Montagna MT, Coretti C, Lovero G, De Giglio O, Montagna O, Laforgia N, Santoro N, Caggiano G.
Int J Mol Sci. 2011;12(9):5871-7.
|
|
|
|
| |
Procalcitonin: a possible marker of invasive fungal infection in high risk patients? |
|
Montagna MT, Coretti C, Caggiano G.
J Prev Med Hyg. 2011 Mar;52(1):38-9.
|
|
|
|
| |
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. |
|
Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing.
Drug Resist Updat. 2010 Dec;13(6):180-95.
|
|
|
|
| |
EUCAST breakpoints for antifungals |
|
Rodriguez-Tudela JL, Arendrup MC, Cuenca-Estrella M, Donnelly JP, Lass-Florl C.
Drug News Perspect 2010; 23: 93-7
|
|
|
|
| |
Evaluation by data mining techniques of fluconazole breakpoints established by the clinical and laboratory standards institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) |
|
Cuesta I, Bielza C, Cuenca-Estrella M, Larrañaga P, Rodríguez-Tudela JL.
Antimicrob Agents Chemother 2010; 54: 1541-6
|
|
|
|
| |
Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). |
|
Montagna MT, Lovero G, De Giglio O, Iatta R, Caggiano G, Montagna O, Laforgia N; AURORA Project Group.
J Prev Med Hyg. 2010 Sep;51(3):125-30
|
|
|
|
| |
Current therapeutic approaches to fungal infections in immunocompromised hematological patients. |
|
Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L.
Blood Rev. 2010 Mar;24(2):51-61. Review.
|
|
|
|
| |
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). |
|
Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D, Bosi A, Candoni A, Locasciulli A, Locatelli F, Menichetti F, Musso M, Viscoli C, Rambaldi A.
Clin Infect Dis. 2009 Oct 15;49(8):1226-36.
|
|
|
|
| |
ZYGOMYCOSIS: current approaches to management of patients with haematological malignancies. |
|
Pagano L, Valentini CG, Caira M, Fianchi L.
Br J Haematol. 2009 Sep;146(6):597-606
|
|
|
|
| |
|
|
|